Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.
Orlent
Hans
H
Department of Gastroenterology and Hepatology, Sint Jan Hospital, Brugge, Belgium.
Mathot
Ron A
RA
Van Bommel
Eric F
EF
Vulto
Arnold G
AG
Schalm
Solko W
SW
Brouwer
Johannes T
JT
D000998:Antiviral Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000821:virology; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D051437:Renal Insufficiency / Q000188:drug therapy / Q000821:virology; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b